FDA Slams Paradigm Insulin Pump by Medtronic, Inc. (MDT) Over Quality Issues
10/17/2013 8:36:46 AM
FDA regulators handed Medtronic a warning letter over issues associated with its Paradigm-branded insulin infusion pumps. This comes on top of a Class I recall this past summer over a faulty part in the infusion pump system. On September 19th, regulators alerted the company to violations found during an inspection of its production facility in Northridge, CA.
Help employers find you! Check out all the jobs and post your resume.
comments powered by